Ultomiris approved to lower protein loss in IgA nephropathy, a kidney disease
Published
FDA granted accelerated approval to AstraZeneca's Ultomiris for adults with IgA nephropathy at risk of getting worse. In a study, it cut protein in the urine by about 47% versus 6% on placebo. Whether it slows kidney decline is still being studied.
Source: Pharmacy Times
This is a plain-language summary. Read the original source for full details.